Stella N. Koliavas

Stella N. Koliavas

Auto-generated profile, based on publicly available information

Stella N. Koliavas

Department of Pathology, University of Colorado Anschutz, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KAKaren L.F. Alvarez-Eraso
Karen L.F. Alvarez-Eraso
MCMaría J. Contreras-Zárate
María J. Contreras-Zárate
AGAndrew Goodspeed
Andrew Goodspeed
JCJames Costello
James Costello
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
DCDiana M. Cittelly
Diana M. Cittelly
Background: Young age is an independent risk factor for the development of breast cancer brain metastases (BM). Prior work showed that 17β-estradiol (E2), the predominant premenopausal hormone, promotes BM of tumors intrinsically unresponsive to E2, in part through modulating estrogen receptor-alpha expressing (ERα⁺) glial cells. However, how E2 reshapes the brain tumor microenvironment (TME), particularly microglia-mediated immunity, and its impact to BM progression remains unclear. Methods: scRNA sequencing and multiparametric flow cytometry were used to define the impact of E2 and E2-suppression on brain immune-cell populations across different stages of BM progression using spontaneous and experimental models of BM. Depletion of microglia and T cell co-cultures were used to study microglia’s role in E2-induced BM. The effects of E2-suppression alone or in combination with whole brain radiotherapy were tested in preclinical models mimicking late-stage BM. Results: E2 repressed immune surveillance and immune activation programs in microglia from early to late stages of brain metastatic progression, suppressing recruitment of effector immune cells to BM. Estrogen suppression, in turn reactivated anti-tumoral signaling in microglia and increased recruitment of effector immune cells to the brain. Microglia from E2-stimulated BM-bearing mice showed decreased ability to induce interferon cytotoxic function and expansion of activated T cells. Conversely, E2-suppression reactivated an effective anti-tumoral response and synergized with RT to significantly decrease BM progression. Conclusion: These findings reveal a previously unrecognized mechanism by which E2 accelerates BC-BM progression through microglial immunosuppression and support evaluation of endocrine therapies as adjunct treatments for ER⁻ brain metastases. Importance of the Study: Standard of care for BM includes stereotactic radiosurgery (SRS) alone or in combination with surgery, systemic chemotherapy or targeted therapies. Our studies show that ovariectomy (which eliminates ovarian E2) and aromatase inhibitors (AIs, which eliminate peripheral E2 synthesis) reduce progression of BM when used in combination with WBRT and in immuno-competent models. We demonstrate E2 promotes an immunosuppressive brain microenvironment from early stages of metastatic progression, in part through modulation of myeloid cells and repression of recruitment of effector T cells to the brain. Thus, these studies suggest that FDA-approved E2-depletion therapies (aromatase inhibitors and selective-estrogen modulators) could be used in combination with brain irradiation to decrease BM progression.

4 August 2026
Verified
Other
Open access
MCMaria J. Contreras-Zárate
Maria J. Contreras-Zárate
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
Ricaurte Alejandro Marquez-OrtizRicaurte Alejandro Marquez-Ortiz
Ricaurte Alejandro Marquez-Ortiz
TPTrinh C. Pham
Trinh C. Pham
SKStella N. Koliavas
Stella N. Koliavas
DCDiana M. Cittelly
Diana M. Cittelly
Effects of genetic or pharmacological TrkB inhibition on astrocyte-conditioned media-induced proliferation and signaling in NSCLC cells

4 August 2026
Verified
Other
Open access
MCMaria J. Contreras-Zárate
Maria J. Contreras-Zárate
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
Ricaurte Alejandro Marquez-OrtizRicaurte Alejandro Marquez-Ortiz
Ricaurte Alejandro Marquez-Ortiz
TPTrinh C. Pham
Trinh C. Pham
SKStella N. Koliavas
Stella N. Koliavas
DCDiana M. Cittelly
Diana M. Cittelly
ENT blocks TrkB activation and proliferation of NSCLC TrkB+ cells lacking NTRK driving mutations. A, Western blot of NSCLC cells plated in phenol red–free media with 2.5% cs-FBS and pretreated for 2 hours with DMSO [vehicle (Veh)], ENT, LOXO101 (LOXO), cyclotraxin (Cyclo), or ANA12 (all drugs at 1 μmol/L), followed by stimulation with 50 ng/mL BDNF for 10 minutes. Tubulin served as a loading control. Densitometric values were calculated as phospho-TrkB/tubulin, total TrkB/tubulin, phospho-AKT/total AKT, and phospho-ERK/total ERK ratios and expressed relative to the Veh control group. B, Proliferation measured as percent confluency (mean ± SEM) using Incucyte live-cell imaging (n = 5 per treatment). Cells were plated in phenol red–free media with 2.5% cs-FBS and treated with Veh, 50 ng/mL BDNF alone, or BDNF combined with 1 μmol/L tyrosine kinase inhibitors. Data were analyzed by repeated-measures two-way ANOVA with post hoc multiple-comparison corrections.

4 August 2026
Verified
Other
Open access
MCMaria J. Contreras-Zárate
Maria J. Contreras-Zárate
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
Ricaurte Alejandro Marquez-OrtizRicaurte Alejandro Marquez-Ortiz
Ricaurte Alejandro Marquez-Ortiz
TPTrinh C. Pham
Trinh C. Pham
SKStella N. Koliavas
Stella N. Koliavas
DCDiana M. Cittelly
Diana M. Cittelly
ENT reduces NSCLC cell proliferation in coculture with astrocytes. Proliferation was quantified as green area (μm2) using live-cell imaging. A, H358; (B) H2030Br3; (C) Lu65; and (D) PC9Br3 cells were cultured either in starvation media (2% cs-FBS) alone or over a 100% confluent monolayer of primary mouse astrocytes, in combination with vehicle (Veh; DMSO) or ENT (1 μmol/L). Data were analyzed by repeated-measures two-way ANOVA followed by Fisher LSD test (n = 5 wells per treatment). P values shown are the adjusted P values for Veh vs. Veh + Ent or Veh-mAst vs. ENT-mAst at the last time point.

4 August 2026
Verified
Other
Open access
MCMaria J. Contreras-Zárate
Maria J. Contreras-Zárate
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
Ricaurte Alejandro Marquez-OrtizRicaurte Alejandro Marquez-Ortiz
Ricaurte Alejandro Marquez-Ortiz
TPTrinh C. Pham
Trinh C. Pham
SKStella N. Koliavas
Stella N. Koliavas
DCDiana M. Cittelly
Diana M. Cittelly
ENT decreased proliferation independently of AKT or ERK signaling pathway in some NSCLC.

4 August 2026
Verified
Other
Open access
MCMaria J. Contreras-Zárate
Maria J. Contreras-Zárate
JJJenny A. Jaramillo-Gómez
Jenny A. Jaramillo-Gómez
Ricaurte Alejandro Marquez-OrtizRicaurte Alejandro Marquez-Ortiz
Ricaurte Alejandro Marquez-Ortiz
TPTrinh C. Pham
Trinh C. Pham
SKStella N. Koliavas
Stella N. Koliavas
DCDiana M. Cittelly
Diana M. Cittelly
Downregulation of TrkB impairs BDNF-TrkB signaling and decreases proliferation induced by astrocytic conditioned media